Product Detail


Share to:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Cas No. 214470-57-2, Methyl 4-(3-chloropropoxy)-5-Methoxy-2-nitrobenzoate

  • 214470-57-2

  • C12H14ClNO6

  • 303.69

  • 1.311±0.06

  • 98%

  • 54-56

  • Philadelphia chromosome-positive chronic myeloid leukemia

  • Bosutinib

  • 8/258/2034 (Bosutinib)

  • Bcr-Abl kinase

  • 2kg

  • CDMO



Bosutinib, a potent tyrosine kinase inhibitor, holds immense promise in the treatment of various cancers, including chronic myeloid leukemia (CML). Our intermediates are meticulously crafted to meet your production needs, ensuring the seamless synthesis of Bosutinib and enabling its widespread availability. Partner with us to make a lasting impact on cancer care, providing patients with a breakthrough therapy that could reshape their lives. Together, let's accelerate the development of Bosutinib and pave the way for improved cancer treatments.